Margetuximab (M) with Retifanlimab (R) in HER2+, PD-L1+1st-line Unresectable/metastatic Gastroesophageal Adenocarcinoma (GEA): MAHOGANY Cohort A
ANNALS OF ONCOLOGY(2021)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined